Ondine Biomedical Announces Share Issuance

 
TIDMOBP 
 
Ondine Biomedical Announces Share Issuance 
FOR:  ONDINE BIOMEDICAL INC. 
 
TSX, AIM SYMBOL:  OBP 
 
March 14, 2011 
 
Ondine Biomedical Announces Share Issuance 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 14, 2011) - Ondine Biomedical Inc. ("Ondine" or the 
"Company") (TSX:OBP)(AIM:OBP) today announced it has issued 88,201 common shares at a weighted average 
price of $0.73 per share to an arm's length supplier as consideration for and in settlement of amounts 
owing in connection with product purchases. The shares are subject to a regulatory hold period in 
Canada which expires on July 12, 2011. Application has been made for these shares to be admitted to 
trading on AIM and dealings are expected to commence on March 17, 2011. 
 
About Ondine Biomedical Inc. 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, 
fungal and viral infections. The Company is focused on developing leading edge products utilizing its 
patented light-activated technology, primarily for the healthcare-associated infection (HAI) market. 
Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and 
spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a 
research and development laboratory in Bothell, Washington, USA. For additional information, please 
visit the Company's website at: www.ondinebio.com. 
 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biomedical Inc. 
Carolyn Cross 
Chairman and CEO 
[e-mail] 
 
OR 
 
Canaccord Genuity Limited 
Mark Williams/Bhavesh Patel 
Nominated Adviser 
[phone] 
 
 
Ondine Biomedical Inc.